A composition for promoting brain cognitive development, its preparation method and application

Abstract

This invention belongs to the field of nutritional composition technology, specifically disclosing a composition for promoting brain cognitive development, its preparation method, and its application. The composition for promoting brain cognitive development provided by this invention includes transforming growth factor, casein phosphopeptide, immunoglobulin, and sn-2 DHA, and further specifies that the mass ratio of transforming growth factor, casein phosphopeptide, immunoglobulin, and sn-2 DHA is (0.1~1.4) ng:(40000~160000) mg:(20000~60000) mg:(20000~70000) mg. In this invention, the preferred ratio of transforming growth factor, casein phosphopeptide, immunoglobulin, and sn-2 DHA can achieve the effect of promoting brain cognitive development through a multi-dimensional synergistic mechanism.

Description

Technical Field

[0001] This invention belongs to the field of nutritional composition technology, and relates to a composition for promoting brain cognitive development, its preparation method and application. Background Technology

[0002] As a key alternative to breast milk, infant formula has always been developed with the core biomimetic goal of "synergistic regulation of multiple active ingredients" in breast milk. Breast milk contains nearly a thousand components such as proteins, HMOs, and lactoferrin, which work synergistically to meet the needs of infants' intestinal, immune, and cognitive development. This is the core direction of formula technology iteration.

[0003] The infant formula industry has undergone four technological upgrades: from optimizing basic nutrient ratios to introducing functional ingredients such as DHA, then to the industrial application of active ingredients like HMOs, and finally to exploring simple combinations of two ingredients. However, it has been difficult to overcome the technological bottleneck of isolated ingredients and single functions, mainly due to the following problems: First, formulas are mostly based on the logic of single ingredients and single functions, ignoring the multi-functional synergy of breast milk; second, ingredient combinations are limited to pairings and focus on a single area, without building a multi-system synergistic system; third, they do not meet the needs of the critical cognitive period of 0-3 years old, lacking "multi-target activation" ingredient combinations, resulting in a significant gap between the formula and the functional simulation of breast milk. In actual application, infants and young children have high requirements for nutritional synergy, and existing formulas are difficult to meet the development of multiple systems, even reducing the utilization rate of ingredients; secondly, existing technologies can no longer match the market's demand for breast milk-like infant formula, and there is an urgent need to build a multi-functional synergistic system of active ingredients to achieve a leap from ingredient replication to functional biomimicry. Summary of the Invention

[0004] In view of this, the present invention provides a composition for promoting brain cognitive development, a method for preparing the composition, and its application.

[0005] To achieve the above-mentioned objectives, the present invention adopts the following technical solution:

[0006] The present invention provides a composition for promoting brain cognitive development, comprising transforming growth factor, casein phosphopeptide, immunoglobulin and sn-2 DHA.

[0007] Through extensive experimentation, the inventors creatively discovered that transforming growth factor, casein phosphopeptide, immunoglobulins, and sn-2 DHA can promote cognitive development through a multi-dimensional synergistic mechanism. In the composition provided by this invention for promoting cognitive development, sn-2 DHA is an important nutrient for neural development. Through the regulation of nerve cells by transforming growth factor, it can promote the rapid entry and accumulation of DHA in the brain, enhancing learning and memory functions. Furthermore, immunoglobulins and casein phosphopeptide can further maintain immune homeostasis, activate the neuroprotective function of B cells, and prevent inflammatory responses and damage to the hippocampus, thereby synergistically promoting cognitive function.

[0008] Preferably, the transforming growth factor is transforming growth factor-β (TgF-β).

[0009] Compared to TgF-α, TgF-β can further improve cognitive development through synergistic effects.

[0010] Preferably, the casein phosphopeptide is β-casein phosphopeptide (β-CPP).

[0011] This invention further specifies that the casein phosphopeptide is β-CPP, which can further maintain immune homeostasis and thus promote brain cognitive development.

[0012] Preferably, the immunoglobulin is immunoglobulin G (IgG).

[0013] Preferably, the content of DHA at position 2 in the sn-2 DHA is 45% to 70%.

[0014] Preferably, the mass ratio of transforming growth factor, casein phosphopeptide, immunoglobulin and sn-2 DHA is (0.1~1.4) ng: (40000~160000) mg: (20000~60000) mg: (20000~70000) mg.

[0015] This invention defines the mass ratio of transforming growth factor, casein phosphopeptide, immunoglobulin, and sn-2 DHA to maximize the synergistic effect of the four components, thereby promoting brain development and significantly improving cognition.

[0016] More preferably, the mass ratio of transforming growth factor, casein phosphopeptide, immunoglobulin and sn-2 DHA is 0.5 ng: 100,000 mg: 40,000 mg: (40,000~70,000) mg.

[0017] When the mass ratio of transforming growth factor, casein phosphopeptide, immunoglobulin, and sn-2 DHA is 0.5 ng: 100,000 mg: 40,000 mg: (40,000~70,000) mg, the DHA content in the hippocampus of the brain accumulates the most, and the latency is shorter in the Morris water maze latency test, which has a significant advantage in promoting brain cognitive development.

[0018] The present invention provides a method for preparing the above-mentioned composition for promoting brain cognitive development, comprising the following steps: mixing the weighed components evenly to obtain the composition for promoting brain cognitive development.

[0019] The present invention provides a product for promoting brain cognitive development, comprising the above-described composition for promoting brain cognitive development.

[0020] Compared with the prior art, the present invention has the following advantages:

[0021] The composition for promoting brain cognitive development provided by this invention, through a multi-dimensional synergistic mechanism among transforming growth factor, casein phosphopeptide, immunoglobulin and sn-2 DHA, can significantly increase the DHA content in the hippocampus of the brain, thereby promoting brain growth and cognitive development. Detailed Implementation

[0022] To make the objectives, technical solutions, and advantages of this invention clearer, the invention will be further described in detail below with reference to embodiments. It should be understood that the specific embodiments described herein are merely illustrative and not intended to limit the invention.

[0023] Lactoferrin was purchased from Hilmar, Inc., USA.

[0024] Unless otherwise specified, the raw materials and reagents used in this invention are all conventional commercially available products; unless otherwise specified, the methods used in this invention are all conventional methods in the field.

[0025] Example 1

[0026] This embodiment provides a composition for promoting brain cognitive development, comprising TgF-β, β-CPP, IgG and sn-2 DHA, wherein the sn-2 DHA content at position 2 is 45%; wherein the mass ratio of TgF-β, β-CPP, IgG and sn-2 DHA is 0.5 ng: 100,000 mg: 40,000 mg: 70,000 mg;

[0027] The above components are mixed evenly to obtain a composition for promoting brain cognitive development.

[0028] Example 2

[0029] This embodiment provides a composition for promoting brain cognitive development, comprising TgF-β, β-CPP, IgG and sn-2 DHA, wherein the sn-2 DHA content at position 2 is 50%; wherein the mass ratio of TgF-β, β-CPP, IgG and sn-2 DHA is 0.5 ng: 100000 mg: 40000 mg: 40000 mg;

[0030] The above components are mixed evenly to obtain a composition for promoting brain cognitive development.

[0031] Example 3

[0032] This embodiment provides a composition for promoting brain cognitive development, comprising TgF-β, β-CPP, IgG and sn-2 DHA, wherein the sn-2 DHA content at position 2 is 66%; wherein the mass ratio of TgF-β, β-CPP, IgG and sn-2 DHA is 0.2 ng: 160000 mg: 20000 mg: 20000 mg;

[0033] The above components are mixed evenly to obtain a composition for promoting brain cognitive development.

[0034] Example 4

[0035] This embodiment provides a composition for promoting brain cognitive development, comprising TgF-β, β-CPP, IgG and sn-2 DHA, wherein the sn-2 DHA content at position 2 is 48%; wherein the mass ratio of TgF-β, β-CPP, IgG and sn-2 DHA is 1.2 ng: 40000 mg: 30000 mg: 50000 mg;

[0036] The above components are mixed evenly to obtain a composition for promoting brain cognitive development.

[0037] Example 5

[0038] This embodiment provides a composition for promoting brain cognitive development, comprising TgF-β, β-CPP, IgG and sn-2 DHA, wherein the sn-2 DHA content at position 2 is 53%; wherein the mass ratio of TgF-β, β-CPP, IgG and sn-2 DHA is 1 ng: 80000 mg: 60000 mg: 30000 mg;

[0039] The above components are mixed evenly to obtain a composition for promoting brain cognitive development.

[0040] Comparative Example 1

[0041] This comparative example provides a composition that differs from Example 1 in that IgG is replaced with lactoferrin.

[0042] The specific composition described above includes TgF-β, β-CPP, lactoferrin, and sn-2 DHA, wherein the DHA content at the 2-position of sn-2 DHA is 45%; and the mass ratio of TgF-β, β-CPP, lactoferrin, and sn-2 DHA is 0.5 ng: 100,000 mg: 40,000 mg: 70,000 mg.

[0043] The above components are mixed evenly to obtain the composition.

[0044] Comparative Example 2

[0045] This comparative example provides a composition that differs from Example 1 in that TgF-β is replaced with insulin-like growth factor (IGF-1).

[0046] The specific composition described above includes IGF-1, β-CPP, IgG and sn-2 DHA, wherein the content of DHA at position 2 in sn-2 DHA is 45%; wherein the mass ratio of IGF-1, β-CPP, IgG and sn-2 DHA is 0.5 ng: 100,000 mg: 40,000 mg: 70,000 mg;

[0047] The above components are mixed evenly to obtain the composition.

[0048] Comparative Example 3

[0049] This comparative example provides a composition that differs from Example 1 in that β-CPP is replaced with choline.

[0050] The specific composition described above includes TgF-β, choline, IgG, and sn-2 DHA, wherein the content of DHA at position 2 in sn-2 DHA is 45%; wherein the mass ratio of TgF-β, choline, IgG, and sn-2 DHA is 0.5 ng: 100,000 mg: 40,000 mg: 70,000 mg;

[0051] The above components are mixed evenly to obtain the composition.

[0052] Example of effect

[0053] The feed formulation used in this embodiment of the invention is as follows:

[0054] The compositions provided in Examples 1-5 and Comparative Examples 1-3 were added to the feed, with the amount of composition added being 0.5% of the feed.

[0055] In this experiment, the rats were fed the standard AIN-93G diet, which consists of seven macronutrient groups, mainly carbohydrates, protein, fat, fiber, minerals, vitamins, and other additives. It was purchased from Jiangsu Xietong Pharmaceutical Biotechnology Co., Ltd. (Jiangsu, China).

[0056] The experimental animals were three-week-old SPF-grade Sprague-Dawley rats, with 10 rats in each treatment group. All rats were purchased from Jiangsu Xietong Pharmaceutical Biotechnology Co., Ltd. (Jiangsu, China).

[0057] Feeding conditions: Each group of rats was fed a diet containing the prescribed compound for a total of 28 days. During the feeding period, feeding and water intake were recorded every 3 days, and weight and body length changes were recorded weekly. Physical injuries and mental state were also examined. The rats were kept in a controlled environment with a 12-hour light / dark cycle, a temperature of 22-25℃, and a humidity of 50%-60%. All rats had free access to food and water.

[0058] 1. Behavioral test results

[0059] During the last 6 days of rearing, the rats underwent Morris water maze training (5 days) and a formal water maze test (1 day). During the Morris water maze training, the rats were placed into the water maze from different quadrants each day to train them to find hidden platforms (the time to find the platform was recorded, i.e., the latency period).

[0060] Water maze formal test (day 28): Remove the platform and record the time required for the rats to find the original platform location;

[0061] This experiment is mainly used to assess spatial learning and memory abilities. Rats need to complete the task by remembering the location of a hidden platform in the water. The platform escape latency (the time required for the rat to find the platform) can be used to measure the rat's learning efficiency and spatial memory ability. This experiment is widely used to study the effects of DHA on hippocampal synaptic plasticity and memory function.

[0062] Statistical analysis was performed using SPSS software. ANOVA was used to compare differences between groups, and multiple post-hoc validations were performed using Tukey's HSD method. The smallest significance level (p-value) was defined as p < 0.05.

[0063] 2. Verification experiment on DHA accumulation in the hippocampus of the brain

[0064] After behavioral testing, rats were dissected, and their brains and other tissues were collected, preserved, weighed, and recorded. Hippocampal samples were taken on ice for examination and staining. Absolute quantitative analysis was used to determine the accumulation level of DHA in the hippocampus, and the mean ± standard deviation was calculated. Statistical analysis was performed using SPSS software, with ANOVA used to compare differences between groups. Significance differences were verified using multiple post-hoc methods, including Tukey's HSD. The smallest significance level (p-value) was defined as p < 0.05.

[0065] Table 1 shows the latency period and the amount of DHA accumulated in the hippocampus of the brain.

[0066] Table 1 Statistical Results

[0067]

[0068] As shown in Table 1, in Examples 1 and 2 of the present invention, when the ratio of TgF-β, β-CPP, IgG, and sn-2 DHA in the composition is limited to (0.1~1.4) ng:(40000~160000) mg:(20000~60000) mg:(20000~70000) mg, the latency period is as low as 44~66 s, and the absolute content of hippocampal DHA reaches 9~13 mg / g; when the ratio of TgF-β, β-CPP, IgG, and sn-2 DHA in the composition is further limited, the latency period is as low as 44~66 s, and the absolute content of hippocampal DHA reaches 9~13 mg / g. When the DHA dosage ratio is between 0.5ng:100000mg:40000mg:(40000~70000)mg, the latency period is as low as 44~46s, and the absolute DHA content in the hippocampus is as high as 12~13mg / g. When the dosage ratio of TgF-β, β-CPP, IgG and sn-2 DHA in the composition is controlled within a specific range, TgF-β, β-CPP, IgG and sn-2 DHA can promote brain cognitive development through a multi-dimensional synergistic mechanism.

[0069] Compared with Example 1, Comparative Example 1 replaced IgG with lactoferrin; Comparative Example 2 replaced TgF-β with IGF-1; and Comparative Example 3 replaced β-CPP with choline. Even when IgG, TgF-β, and β-CPP were replaced with lactoferrin, IGF-1, and choline, which have similar functions, the results in Table 1 show that the latency period was significantly longer than that of Example 1, and the absolute content of DHA in the hippocampus was significantly lower than that of Example 1. It can be seen that only when the composition provided by the present invention is TgF-β, β-CPP, IgG, and sn-2 DHA can the effect of promoting brain cognitive development be significantly achieved.

[0070] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions or improvements made within the spirit and principles of the present invention should be included within the protection scope of the present invention.

Claims

1. A composition for promoting cognitive brain development, characterized in that: It includes transforming growth factor, casein phosphopeptide, immunoglobulin, and sn-2 DHA; the transforming growth factor is transforming growth factor-β; the immunoglobulin is immunoglobulin G; The mass ratio of transforming growth factor, casein phosphopeptide, immunoglobulin and sn-2 DHA is (0.1~1.4) ng: (40000~160000) mg: (20000~60000) mg: (20000~70000) mg.

2. The composition for promoting cognitive brain development as described in claim 1, characterized in that: The casein phosphopeptide is β-casein phosphopeptide.

3. The composition for promoting cognitive brain development as described in claim 1, characterized in that: The sn-2 DHA contains 45% to 70% DHA at the 2-position.

4. The composition for promoting cognitive brain development as described in claim 1, characterized in that: The mass ratio of transforming growth factor, casein phosphopeptide, immunoglobulin and sn-2 DHA is 0.5 ng: 100,000 mg: 40,000 mg: (40,000~70,000) mg.

5. A method for preparing the composition for promoting brain cognitive development according to any one of claims 1 to 4, characterized in that: Includes the following steps: The weighed components are mixed evenly to obtain a composition for promoting brain cognitive development.

6. A product that promotes brain cognitive development, characterized in that: Includes the composition for promoting brain cognitive development as described in any one of claims 1 to 4.

Images